Competing interests
NS reports serving on advisory boards of Syndax and Kura Oncology. ARB reports intellectual property rights from SOPHiA Genetics. MDE reports speaking fees from Illumina, consulting for Pillar Biosciences, and advisory board membership for Arima Genomics. MEA reports speaking fees from Biocartis, i3health, consulting for Janssen Global Services, Bristol-Myers Squibb, AstraZeneca, Roche, Biocartis, Sanofi, and intellectual property rights from SOPHiA Genetics. Michael Berger reports personal fees from AstraZeneca, Paige.AI and intellectual property rights from SOPHiA Genetics, and a provisional patent for Systems and methods for detecting cancer via cfDNA screening. RLL is a former member of the Supervisory Board and current SAB member for Qiagen (compensation/equity), a co-founder at Ajax (equity), a board member of the Mark Foundation for Cancer Research, and a former scientific advisor to Mission Bio, Kurome, Syndax, Scorpion, Zentalis, Jubilant, Auron, Prelude, and C4 Therapeutics. For each of these entities, he received equity/compensation. He has received research support from the Cure Breast Cancer Foundation (with IP rights), Calico, Zentalis, and Ajax, and has consulted/provided professional services for ECOG-ACRIN, Genome Canada, Goldman Sachs, and AstraZeneca. EMS reports advisory/consulting services for Syndax, Kura Oncology, Johnson and Johnson, Charm Therapeutics. RS reports royalties received from SOPHiA Genetics for MSK-IMPACT and MSK-ACCESS. SFC is a consultant and/or shareholder for Daiichi-Sankyo, Stelexis BioSciences, and Ursamin, none of which are directly related to the content of this paper; he received research support from Syndax, Trio, and Actinium and is an inventor on a patent related to MEN1 mutations and uses thereof (WO2024112819A1). All other authors report no related conflicts of interest.
